Trial
NCT00565227
Phase I Study of Vorinostat in Combination With Docetaxel in Patients With Advanced and Relapsed Solid Malignancies.
Phase ITERMINATEDSAFETYConfidence: HIGH
Sponsor
University of Michigan Rogel Cancer Center
Collaborators
—
Condition
Non-Small-Cell Lung Carcinoma
Intervention
vorinostat (suberoylanilide hydroxamic acid)
Why stopped
closed due to toxicity
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2016-12-02